{"component": "definition", "props": {"groups": [{"snippet_links": [], "samples": [{"hash": "8GRO6rsMFJY", "uri": "/contracts/8GRO6rsMFJY#lead-indication", "label": "License and Option Agreement (Jazz Pharmaceuticals PLC)", "score": 36.5947990417, "published": true}, {"hash": "69j8zAQtheF", "uri": "/contracts/69j8zAQtheF#lead-indication", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "8osnJoSuIky", "uri": "/contracts/8osnJoSuIky#lead-indication", "label": "License and Option Agreement (Pfenex Inc.)", "score": 27.8555774689, "published": true}], "snippet": "has the meaning set forth in Exhibit E.", "size": 6, "hash": "f436dd23803fb5095a23228e2815851e", "id": 1}, {"snippet_links": [], "samples": [{"hash": "gltSt3hDb69", "uri": "/contracts/gltSt3hDb69#lead-indication", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "4JdsVkKhxkP", "uri": "/contracts/4JdsVkKhxkP#lead-indication", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "gnmJrczAfwx", "uri": "/contracts/gnmJrczAfwx#lead-indication", "label": "License Agreement (Global Blood Therapeutics, Inc.)", "score": 30.2375087738, "published": true}], "snippet": "means Sickle Cell Disease (SCD).", "size": 4, "hash": "d6d8d5ee0cbb8fb0d34bdaf37e2cae30", "id": 2}, {"snippet_links": [{"key": "treatment-of", "type": "definition", "offset": [10, 22]}, {"key": "adult-patients", "type": "definition", "offset": [23, 37]}], "samples": [{"hash": "gF1XZyS0Nde", "uri": "/contracts/gF1XZyS0Nde#lead-indication", "label": "License Agreement (Spectrum Pharmaceuticals Inc)", "score": 24.603012085, "published": true}, {"hash": "2Lq6aiQLuOa", "uri": "/contracts/2Lq6aiQLuOa#lead-indication", "label": "License, Development and Commercialization Agreement (Allos Therapeutics Inc)", "score": 22.5879535675, "published": true}, {"hash": "lo2gzG4L5LC", "uri": "https://investor.sppirx.com/index.php/static-files/28c8346c-400f-4918-b67a-598c9a099178", "label": "investor.sppirx.com", "score": 9.96235466, "published": false}], "snippet": "means the treatment of adult patients with relapsed or refractory PTCL, where \u201cPTCL\u201d for this purpose is defined by the population included in the \u201cPROPEL\u201d study (PDX-008) or any subset(s) of such population.", "size": 4, "hash": "3736aa4ee632ffd2187fe5cd4f8f8e9b", "id": 3}, {"snippet_links": [], "samples": [{"hash": "1wvcqusdNwO", "uri": "/contracts/1wvcqusdNwO#lead-indication", "label": "Development License and Option Agreement (Receptos, Inc.)", "score": 24.2881584167, "published": true}, {"hash": "1n7D4Xgt204", "uri": "/contracts/1n7D4Xgt204#lead-indication", "label": "Development License and Option Agreement (Receptos, Inc.)", "score": 24.2553043365, "published": true}, {"hash": "gefH1jJSl0R", "uri": "/contracts/gefH1jJSl0R#lead-indication", "label": "Development License and Option Agreement (Receptos, Inc.)", "score": 24.1184120178, "published": true}], "snippet": "means Eosinophilic Esophagitis.", "size": 3, "hash": "6ec78fdbacab950706f16f85b2c402ca", "id": 4}, {"snippet_links": [{"key": "treatment-of", "type": "definition", "offset": [6, 18]}], "samples": [{"hash": "9ZHrVv6LDLX", "uri": "/contracts/9ZHrVv6LDLX#lead-indication", "label": "Development and Commercial License Agreement (Starton Holdings, Inc.)", "score": 37.1943874059, "published": true}, {"hash": "k2GW9Lt6y8T", "uri": "/contracts/k2GW9Lt6y8T#lead-indication", "label": "Development and Commercial License Agreement (HWEL Holdings Corp.)", "score": 34.527721405, "published": true}], "snippet": "means treatment of chemotherapy induced nausea and vomiting.", "size": 2, "hash": "bf0edf85dfd65ebf70f8a14f377f441e", "id": 5}, {"snippet_links": [{"key": "collaboration-agreement", "type": "definition", "offset": [57, 80]}], "samples": [{"hash": "8HU988uZL1D", "uri": "/contracts/8HU988uZL1D#lead-indication", "label": "Contingent Value Rights Agreement (Allos Therapeutics Inc)", "score": 23.2614650726, "published": true}, {"hash": "9vp4g4bME0b", "uri": "/contracts/9vp4g4bME0b#lead-indication", "label": "Contingent Value Rights Agreement (Spectrum Pharmaceuticals Inc)", "score": 23.25872612, "published": true}], "snippet": "shall have the meaning ascribed to it in the Mundipharma Collaboration Agreement.", "size": 2, "hash": "388e139da85ff021acab3076ac99ef1b", "id": 6}, {"snippet_links": [{"key": "treatment-of", "type": "definition", "offset": [10, 22]}], "samples": [{"hash": "6LcqlDu8tgn", "uri": "/contracts/6LcqlDu8tgn#lead-indication", "label": "Development and License Agreement (Ilex Oncology Inc)", "score": 18.0, "published": true}, {"hash": "5wjnrVAWD3a", "uri": "/contracts/5wjnrVAWD3a#lead-indication", "label": "Development and License Agreement (Ilex Oncology Inc)", "score": 18.0, "published": true}], "snippet": "means the treatment of glioblastoma multiforma.", "size": 2, "hash": "1ea07559d6fac38ca0b702f44b348dfb", "id": 7}, {"snippet_links": [{"key": "development-plan", "type": "clause", "offset": [52, 68]}], "samples": [{"hash": "7b6oQdTGEWS", "uri": "/contracts/7b6oQdTGEWS#lead-indication", "label": "Collaboration and License Agreement (aTYR PHARMA INC)", "score": 31.0889797211, "published": true}, {"hash": "3bNXmiqHilg", "uri": "https://investors.atyrpharma.com/static-files/810f2b54-f4f8-4088-aff3-119fdf3d30f9", "label": "investors.atyrpharma.com", "score": 10.0636548996, "published": false}], "snippet": "means the ILD Indication identified in the approved Development Plan as the Lead Indication, which will initially be pulmonary sarcoidosis.", "size": 2, "hash": "cd5b59f2acdd9c4db3bce0c38dcd30a3", "id": 8}, {"snippet_links": [{"key": "this-agreement", "type": "clause", "offset": [52, 66]}], "samples": [{"hash": "fLUP9YOmwa3", "uri": "/contracts/fLUP9YOmwa3#lead-indication", "label": "Collaboration Agreement (Acorda Therapeutics Inc)", "score": 21.0, "published": true}, {"hash": "4Z5IECp9ij", "uri": "/contracts/4Z5IECp9ij#lead-indication", "label": "Collaboration Agreement (Acorda Therapeutics Inc)", "score": 21.0, "published": true}], "snippet": "has the meaning ascribed to it in Section 3.2(a) of this Agreement.", "size": 2, "hash": "d2ce7968ee95bceecb63628c9c117356", "id": 9}, {"snippet_links": [{"key": "colorectal-cancer", "type": "clause", "offset": [6, 23]}, {"key": "initial-development-plan", "type": "definition", "offset": [61, 85]}], "samples": [{"hash": "4DMBPjjeJmf", "uri": "/contracts/4DMBPjjeJmf#lead-indication", "label": "License Agreement (HUTCHMED (China) LTD)", "score": 34.1581115723, "published": true}], "snippet": "means colorectal cancer, as more particularly defined in the initial Development Plan.", "size": 1, "hash": "fd2c7d1fab02c23d5cbb9fe38214ad26", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYbGVhZC1pbmRpY2F0aW9uIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Lead Indication", "snippet": "has the meaning set forth in Exhibit E.", "size": 35, "id": "lead-indication", "examples": ["After Jazz has obtained Regulatory Approval for a HemOnc Product, Jazz shall use Commercially Reasonable Efforts to Commercialize such HemOnc Product for the <strong>Lead Indication</strong> in the United States.", "For clarity, GBT shall pay to Roche up to forty million, five hundred thousand US Dollars (US$40,500,000) for achievement of the events in the <strong>Lead Indication</strong> and nineteen million, two hundred fifty thousand US Dollars (US$19,250,000) for achievement of the events in the Other Indication(s)).", "After the expiration of the applicable Assessment Period, Jazz shall use Commercially Reasonable Efforts to Develop the HemOnc Products for the <strong>Lead Indication</strong> in the United States and to achieve the Development milestones numbered 5 and 6 referenced in Exhibit 6.3 that specifically relate to the <strong>Lead Indication</strong> in the United States.", "For clarity, Jazz\u2019s Development obligations under this Section 4.4 do not require Jazz to Develop the HemOnc Products in more than one subtype, subgroup, or line of treatment for the <strong>Lead Indication</strong>.", "GBT shall pay to Roche up to a total of fifty nine million, seven hundred fifty thousand US Dollars (US$59,750,000) in relation to the achievements of (i) the development events as described in the following schedule for any Product that achieves such event in <strong>Lead Indication</strong> first and (ii) the development events as described in the following schedule for any Product that achieves such event in Other Indication(s) first.", "For clarity, Jazz\u2019s Commercialization obligations under this Section 5.2 do not require Jazz to Commercialize the applicable HemOnc Product in more than one subtype, subgroup, or line of treatment of the <strong>Lead Indication</strong>.", "Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data or pertains to results of clinical studies, or other studies with respect to any Licensed Compound in the <strong>Lead Indication</strong> or that includes Confidential Information of the other Party.", "Following delivery of the Complete Data Package to AbbVie as contemplated by Section 3.3.1(i), Receptos shall exercise Commercially Reasonable Efforts to meet with the FDA regarding the status of Development for ABT-308 in the <strong>Lead Indication</strong> with a goal of assessing whether such Development may proceed directly to the initiation of a Phase 3 without another Phase 2 (the \u201cFDA Post-Study Meeting\u201d).", "The Parties shall work cooperatively to develop a form Third Party clinical study, laboratory service and consulting agreement that Receptos will use to carry out its activities and obligations to Develop the Licensed Compound in the <strong>Lead Indication</strong> in accordance with the Development Plan and Budget (each a \u201cClinical Study Related Agreement\u201d).", "A Collaboration Development Plan and Budget for the joint program of Development with respect to ABT-308 for the <strong>Lead Indication</strong>, which plan shall assign responsibility between the Parties based on capabilities, familiarity and experience with respect to ABT-308 for the <strong>Lead Indication</strong>, shall be attached as a schedule to the Collaboration Agreement."], "related": [["second-indication", "Second Indication", "Second Indication"], ["first-indication", "First Indication", "First Indication"], ["initial-indication", "Initial Indication", "Initial Indication"], ["additional-indication", "Additional Indication", "Additional Indication"], ["collaboration-product", "Collaboration Product", "Collaboration Product"]], "related_snippets": [], "updated": "2026-03-15T05:55:41+00:00"}, "json": true, "cursor": ""}}